Golidocitnib

Developed for: chronic lymphoproliferative disorder of NK-cells · mycosis fungoides · T-cell large granular lymphocyte leukemia
Investigated by: Henan Cancer Hospital · Institute of Hematology & Blood Diseases Hospital, China · Second Xiangya Hospital of Central South University · The First Affiliated Hospital of Air Force Medicial University · The First Affiliated Hospital of Nanchang University · The First Hospital of Jilin University
+2 more
· Tianjin First Central Hospital · Tongji Hospital

today NCT06716658 · Ph 2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06716658	Dec 2024 → Nov 2026 expected	T-cell large granular lymphocyte leukemia, chronic lymphoproliferative disorder of NK-cells, mycosis fungoides	Institute of Hematology & Blood Diseases Hospital, China	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Golidocitnib	“Golidocitnib150mg QD orally, with a 28-day cycle” NCT06716658 ↗
Route	Oral	“Golidocitnib150mg QD orally” NCT06716658 ↗